For laboratory research education only. This article summarizes published scientific literature and regulatory documents. It is not medical advice. Research-grade tirzepatide is not an FDA-approved drug, is not equivalent to any approved product, and is not for human or animal use or consumption. People should use only FDA-approved medicines prescribed by a licensed clinician.
Tirzepatide is a synthetic 39-amino-acid peptide developed by Eli Lilly and Company under the code LY3298176. It activates two hormone receptors, the GIP receptor and the GLP-1 receptor, which makes it a “dual agonist” (FDA label).
Tirzepatide was the first dual GIP/GLP-1 agonist to reach the market. FDA first approved it in 2022 as the prescription medicine Mounjaro for type 2 diabetes, and in 2023 as Zepbound for chronic weight management (Wikipedia). Those approvals cover Lilly’s manufactured products only. They do not extend to tirzepatide made or sold by anyone else.
This guide covers tirzepatide’s molecular design, how dual agonism works, the major clinical trial programs, labeled safety information, and its regulatory status as of November 2026. For background on the receptor families, see GLP-1, GIP, and Glucagon: How Single, Dual, and Triple Receptor Agonists Differ.
Molecular Identity
Tirzepatide’s sequence is based on the natural GIP hormone, modified so it also activates the GLP-1 receptor (FDA label, section 11).
| Property | Value |
|---|---|
| Development code | LY3298176 |
| Developer | Eli Lilly and Company |
| Peptide length | 39 amino acids, linear |
| Non-standard residues | Aib (2-aminoisobutyric acid) at positions 2 and 13; C-terminal amide |
| Lipidation | Lysine at position 20 linked to 1,20-eicosanedioic acid (a C20 fatty diacid) through a linker |
| Molecular formula | C225H348N48O68 |
| Molecular weight | 4813.53 Da |
| CAS number | 2023788-19-2 |
| Reported elimination half-life | About 5 days |
Formula, molecular weight, and structure per the FDA-approved label; CAS, code, and half-life per Wikipedia.
The C20 fatty diacid binds albumin in blood and slows clearance, which gives the long half-life behind once-weekly use in approved products. The Aib residues protect against breakdown by DPP-4, the enzyme that inactivates natural GIP and GLP-1 within minutes. Retatrutide uses the same two design strategies with an added glucagon-receptor component.
How Dual Agonism Works
GIP and GLP-1 are both incretins: gut hormones released after eating that increase insulin secretion when blood glucose is elevated. Tirzepatide activates both receptors with a single molecule.
| Receptor | Natural hormone | Main roles studied in metabolic research |
|---|---|---|
| GLP-1 receptor | Glucagon-like peptide-1 | Glucose-dependent insulin release, reduced glucagon secretion, slower gastric emptying, appetite signaling in the brain |
| GIP receptor | Glucose-dependent insulinotropic polypeptide | Glucose-dependent insulin release; effects on fat tissue and appetite pathways |
| Compound class | Receptors engaged | Example (status) |
|---|---|---|
| Single agonist | GLP-1 | Semaglutide (FDA approved) |
| Dual agonist | GIP + GLP-1 | Tirzepatide (FDA approved as Mounjaro and Zepbound) |
| Triple agonist | GIP + GLP-1 + glucagon | Retatrutide (investigational) |
The FDA label describes tirzepatide as acting on both receptors and lowering fasting and post-meal glucose, reducing food intake, and lowering body weight in the studied populations (FDA label). How much of each effect comes from the GIP component versus the GLP-1 component is still an active research question. For a fuller comparison of the three receptor families, see our GLP-1, GIP, and glucagon explainer.
Clinical Evidence
Tirzepatide has been studied in large Phase 3 programs. Lilly ran the SURPASS trials in type 2 diabetes and the SURMOUNT trials in obesity, all under medical supervision with Lilly-manufactured drug. The key studies are summarized below.
| Trial | Population | Participants | Length | Reported result | Source |
|---|---|---|---|---|---|
| SURMOUNT-1 | Adults with obesity or overweight, no diabetes | 2,539 | 72 weeks | −20.9% body weight on highest dose vs. −3.1% placebo | ACC summary |
| SURMOUNT-5 | Adults with obesity or overweight, no diabetes; head-to-head vs. semaglutide | 751 | 72 weeks | −20.2% vs. −13.7% body weight | Lilly, May 2025 |
| SURPASS-CVOT | Adults with type 2 diabetes and established cardiovascular disease; vs. dulaglutide | 13,299 | Median ≈4 years | Non-inferior on major cardiovascular events (HR 0.92); superiority not shown | HCPLive, Aug 2026 |
Weight regain after stopping. In the SURMOUNT-1 extension, participants regained weight during an off-treatment period (ACC).
What these trials do and don’t show. Each result reflects controlled use of an approved, quality-assured product with medical monitoring and lifestyle intervention. None of it can be assumed to apply to tirzepatide from unapproved sources, whose identity, purity, and sterility are unverified.
Labeled Safety Information
Because tirzepatide is an approved medicine, its safety profile is set out in FDA-approved prescribing information. The label below applies to Lilly’s approved products, not to research materials (Zepbound label, rev. 04/2026).
Boxed warning. Tirzepatide caused thyroid C-cell tumors in rats. Whether this applies to humans is unknown. The label contraindicates use in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Warnings and precautions in the label:
- Severe gastrointestinal adverse reactions
- Acute kidney injury related to volume depletion
- Acute gallbladder disease
- Acute pancreatitis
- Hypersensitivity reactions
- Hypoglycemia, particularly with insulin or sulfonylureas
- Diabetic retinopathy complications in people with type 2 diabetes
- Pulmonary aspiration during general anesthesia or deep sedation
Most common adverse reactions (≥5%) listed in the label include nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions, fatigue, hypersensitivity reactions, belching, hair loss, and reflux.
In SURMOUNT-1, discontinuation because of adverse events ranged from 4.3% to 7.1% across doses, versus 2.6% on placebo (ACC).
Regulatory and Legal Status as of November 2026
Tirzepatide is FDA approved only as Lilly’s Mounjaro and Zepbound, for the specific uses on their labels. Any other tirzepatide product, including material sold as “research use only,” is not an approved drug.
| Date | Development | Source |
|---|---|---|
| Aug 28, 2026 | Mounjaro approved to lower the risk of major cardiovascular events in high-risk adults with type 2 diabetes, based on SURPASS-CVOT | HCPLive |
| Aug 2026 | FDA warning letters to online sellers marketing GLP-1 peptides, including tirzepatide, with “research use only” or “not for human consumption” labels; FDA found the overall marketing showed intended human use | McDermott Will & Schulte; Sheppard Mullin |
| Apr 7, 2026 | FDA published seven warning letters to online “research peptide” sellers of GLP-1 products | Policy Canary |
| Early 2025 | FDA’s grace period for pharmacies compounding tirzepatide under shortage rules ended | Foley & Lardner |
| Dec 19, 2024 | FDA re-confirmed that the tirzepatide shortage was resolved | Foley & Lardner |
| Dec 2024 | Zepbound approved for moderate-to-severe obstructive sleep apnea in adults with obesity | Lilly |
| Nov 2023 | Zepbound approved for chronic weight management | Wikipedia |
| May 2022 | Mounjaro approved for type 2 diabetes in adults | Wikipedia |
Compounding. During the 2022–2024 shortage, pharmacies were temporarily allowed to compound tirzepatide. That allowance depended on the shortage and ended once FDA declared it resolved (Foley & Lardner).
“Research use only” labels. FDA judges a product by its overall marketing, not by a disclaimer alone. Sellers whose sites included dosing, injection guidance, or weight-loss claims have been treated as selling unapproved drugs, and FDA has also treated bundled bacteriostatic water as an unapproved drug in that context (McDermott Will & Schulte). Tirzepatide is not among the peptides in HHS’s October 2026 interim compounding policy (AJMC).
Analytical Identity and Quality Testing
Tirzepatide is a 4.8 kDa lipidated peptide, so confirming identity and purity takes more than a basic purity check. Laboratory characterization of any research lot should include:
- Mass spectrometry confirming an intact mass consistent with the labeled 4813.5 Da. Peptides this size appear as several multiply charged ions, so the deconvoluted mass should be reported (HPLC vs. LC-MS).
- Reversed-phase HPLC purity as percent peak area, with enough separation to resolve closely related impurities such as variants missing the fatty-acid side chain.
- Lot number, test date, and testing laboratory, so results can be traced to a specific vial (How to Read a COA).
A certificate of analysis describes a research material’s chemistry. It does not make the material equivalent to an FDA-approved product, which is also controlled for sterility, endotoxins, formulation, and manufacturing under current Good Manufacturing Practice.
Frequently Asked Questions
What is tirzepatide?
A 39-amino-acid synthetic peptide from Eli Lilly (LY3298176) that activates the GIP and GLP-1 receptors. It is the active ingredient in the FDA-approved medicines Mounjaro and Zepbound.
Is tirzepatide FDA approved?
Only as Lilly’s Mounjaro and Zepbound, for the uses on their labels. Tirzepatide sold by other sources, including research-grade material, is not an approved drug.
How is tirzepatide different from semaglutide and retatrutide?
Semaglutide activates the GLP-1 receptor only. Tirzepatide adds GIP receptor activity. Retatrutide, which is still investigational, adds glucagon receptor activity as well. See GLP-1, GIP, and Glucagon.
What did the major trials show?
In SURMOUNT-1, the highest dose produced an average 20.9% body-weight reduction at 72 weeks versus 3.1% on placebo. In SURMOUNT-5, tirzepatide produced greater weight reduction than semaglutide.
What is the boxed warning?
The label warns that tirzepatide caused thyroid C-cell tumors in rats and that the human relevance is unknown. Use is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
Can tirzepatide still be compounded?
The shortage-based allowance ended after FDA declared the shortage resolved in late 2024. Tirzepatide is not covered by HHS’s October 2026 interim peptide policy.
Does a certificate of analysis make research tirzepatide equivalent to Mounjaro or Zepbound?
No. A COA documents identity and purity. Approved products are also controlled for sterility, formulation, and manufacturing quality, and only they are approved for use in people.
Related Research Library Articles
- GLP-1, GIP, and Glucagon: How Single, Dual, and Triple Receptor Agonists Differ
- What Are Peptides?
- What Are Research Peptides?
- What Is MOTS-c?
- HPLC vs. LC-MS: Understanding Peptide Purity and Identity Testing
- Peptide Certificate of Analysis: How to Read a COA
References
- U.S. FDA. Zepbound (tirzepatide) injection prescribing information, revised 04/2026. accessdata.fda.gov
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038
- American College of Cardiology. SURMOUNT-1 trial summary. ACC
- Eli Lilly and Company. Zepbound showed superior weight loss over Wegovy in complete SURMOUNT-5 results. May 11, 2025. Lilly
- HCPLive. Tirzepatide gets FDA approval to cut cardiovascular risk in type 2 diabetes (SURPASS-CVOT). August 28, 2026. HCPLive
- Eli Lilly and Company. FDA approves Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. December 20, 2024. Lilly
- Foley & Lardner. GLP-1 drugs: FDA re-confirms decision removing tirzepatide from the drug shortage list. December 2024. Foley
- McDermott Will & Schulte. Client alert on FDA warning letters to online peptide sellers. 2026. McDermott
- Sheppard Mullin. FDA balances peptide policy with enforcement against unlawful peptide sellers. September 2026. Sheppard Mullin
- Policy Canary. FDA hits seven peptide websites in a single day. April 2026. Policy Canary
- AJMC. 5 things to know about HHS’s interim peptide compounding policy. October 2026. AJMC
- Wikipedia. Tirzepatide (identifiers and approval history). Wikipedia
Research use only. This article is for laboratory research education. Research-grade tirzepatide is not an FDA-approved drug and is not equivalent to Mounjaro, Zepbound, or any approved product. It is not a food, dietary supplement, or cosmetic, and it is not for human or animal use or consumption. Nothing here is medical advice or a recommendation to use any substance. This article summarizes published literature and regulatory documents as of November 2, 2026.
Leave a Reply